Statement of Principles concerning Huntington disease (Balance of Probabilities) (No. 50 of 2023)

The instrument relies on a small set of tightly framed legal concepts and definitions that determine its scope and operation.

Huntington disease: The Statement provides a substantive medical definition in subsection 7(2): a genetic disorder of the brain with progressive degeneration of nerve cells in the basal ganglia and cortex, producing motor, emotional and cognitive dysfunction. The instrument expressly treats nomenclature and coding as secondary: although the condition aligns with ICD‑10‑AM code G10, the statutory meaning is the textual definition in subsection 7(2) (subsections 7(3)-(4)). The Statement extends to death from Huntington disease where death results from a terminal event or condition contributed to by the person’s Huntington disease (subsection 7(5)). Schedule 1 defines “terminal event” by way of examples, including pneumonia, respiratory failure, cardiac arrest, circulatory failure and cessation of brain function (Schedule 1: terminal event).

Standard of proof: The Authority records its view, on the sound medical‑scientific evidence available, that it is more probable than not that Huntington disease and death from Huntington disease can be related to relevant service (section 8). The instrument is therefore framed to be applied on the balance of probabilities when assessing individual claims.

Factors model: Rather than attempting an exhaustive list of causal pathways, the Statement operates a factors model in which at least one prescribed factor must exist before a connection is established (section 9). The only factor listed is inability to obtain appropriate clinical management for Huntington disease (subsection 9(1)). Section 11 adds that where a factor in this Statement refers to an injury or disease that has its own Statement of Principles, the factors in that other Statement apply according to its terms.

Relationship to service: Section 10 requires that any factor identified in section 9 be related to the person’s relevant service. Subsection 10(2) narrows the operation of the inability to obtain appropriate clinical management factor: it applies only to material contribution to, or aggravation of, Huntington disease where the disease was suffered or contracted before or during, but did not arise out of, the person’s relevant service. This establishes a temporal and causative limitation on the single listed factor.

Interaction with other instruments and classification systems: The instrument cross‑references the VEA and MRCA (Schedule 1 definitions), the ICD‑10‑AM coding system (subsections 7(3)-(4)) and prior Statements of Principles (section 4). It is made under s 196B(3) of the VEA (section 3) and expressly repeals the earlier Huntington's chorea Statement No. 38 of 2015 (section 4).

Definitions and scope: Schedule 1 collects key definitions that shape who is captured by “relevant service” and how death is characterised. Relevant service is defined in three subcategories that include eligible war service (other than operational service), defence service (other than hazardous service and British nuclear test defence service) and peacetime service under the MRCA (Schedule 1: relevant service). These definitional choices determine which categories of veterans and members may seek to rely on the Statement in claims.

In sum, the main conceptual architecture is compact: a statutory medical definition, a single determinative factor, a relationship requirement linking that factor to defined classes of relevant service, and cross‑referencing to other Statements and classification systems.

The instrument affects claimants and decision‑makers within the veterans’ compensation and military rehabilitation frameworks. By its terms it applies to claims to which section 120B of the VEA or section 339 of the MRCA applies (section 5). Those references identify the procedural contexts in which the Statement will be used by decision‑makers when determining whether Huntington disease or death from Huntington disease is connected with the person’s relevant service.

Claimants: The primary class affected are persons asserting a claim that Huntington disease or death from Huntington disease is connected with relevant service. “Relevant service” is defined in Schedule 1 to mean one of the following: eligible war service (other than operational service) under the VEA; defence service (other than hazardous service and British nuclear test defence service) under the VEA; or peacetime service under the MRCA (Schedule 1: relevant service). Those definitions exclude certain categories (for example operational service and hazardous service are expressly disallowed in the relevant service definition), so not every veteran or former member will fall within the eligible categories for which this Statement will be applied.

Veterans’ entitlements and MRCA applicants: Because the instrument is made under the VEA and expressly links to the MRCA, it affects decision‑makers and applicants under both regimes. The Repatriation Medical Authority (RMA) determined the Statement under subsection 196B(3) of the VEA (section 3), and the instrument is addressed to claims within the statutory machinery of the VEA and the MRCA (section 5). Therefore entitlement seekers under either statute who assert a service connection for Huntington disease must be assessed against the factors, definitions and relationship tests in this Statement.

Decision‑makers and assessors: Members of the RMA, medical assessors, and adjudicators who apply the VEA and MRCA will use this Statement as the authoritative set of factors to determine whether, on the balance of probabilities, Huntington disease or death from Huntington disease is connected with relevant service (section 8). The instrument constrains their inquiry to the defined condition, the listed factor(s), and the relationship criteria in sections 9-11.

Other Statements and cross‑affected claimants: Section 11 provides that if a factor in section 9 refers to an injury or disease covered by another Statement of Principles, then the factors in that other Statement apply. That means practitioners and claimants must consider whether the inability to obtain appropriate clinical management intersects with other Statements. For example, if the factor’s operation raises issues that are the subject of another Statement, those provisions will govern how the factor is applied.

Indirectly affected parties: Medical practitioners, healthcare providers and legal representatives involved in preparing evidence or advising claimants will be affected insofar as their roles intersect with the evidentiary and causal questions set out in this instrument. However, the instrument itself does not impose duties on healthcare providers; it establishes assessment criteria for statutory decision‑makers.

Replaced Statement’s constituency: Section 4 repeals the prior Statement No. 38 of 2015. Claims that were being considered under the old Statement will now be subject to this instrument from its commencement date (section 2). That repeal may change the framework used to assess ongoing or future claims.

In sum, this Statement primarily governs claimants with Huntington disease or death from Huntington disease seeking connection with defined categories of relevant service, and the decision‑makers who must apply the Statement when determining such claims under the VEA and MRCA.

The Statement is not framed as a statute imposing duties or creating enforceable rights in the conventional legislative sense. Instead, it prescribes the factors and definitions that decision‑makers must apply when determining whether Huntington disease or death from Huntington disease is connected with relevant service for claims under the VEA and MRCA. The legal operation is one of definition and assessment rather than of positive obligations on third parties.

Duty of the Repatriation Medical Authority: The instrument records that it was determined by the RMA under subsection 196B(3) of the VEA (section 3). That statutory mechanism obliges the RMA to set Statements of Principles for relevant injuries and diseases; this instrument is the RMA exercising that statutory function. The instrument is therefore the RMA’s expression of the relevant scientific and medical view for decision‑making contexts.

Decision‑makers’ obligation to apply the Statement: By applying the VEA and MRCA statutory schemes, decision‑makers are required to consider established Statements of Principles when assessing connection with service. Section 8 states the RMA’s view that, on the sound medical‑scientific evidence available, it is more probable than not that Huntington disease and death from Huntington disease can be related to relevant service. The practical effect is that adjudicators must apply this Statement and its factors when determining whether a claim meets the statutory tests in the applicable Acts (see section 5 linking to the VEA and MRCA). The Statement prescribes the legal tests that adjudicators must use to judge causation: at least one of the listed factors in section 9 must exist and be related to the relevant service (sections 9-10).

Claimant’s burden: The Statement establishes the form of causal link that must be shown. The instrument expressly says that “at least one of the following factors must exist before it can be said that, on the balance of probabilities, Huntington disease or death from Huntington disease is connected with the circumstances of a person’s relevant service” (section 9). Therefore, claimants must persuade decision‑makers on the balance of probabilities that one or more listed factors exist and relate to the person’s relevant service. The Statement further narrows application of the inability to obtain appropriate clinical management factor to situations where the disease was suffered or contracted before or during, but did not arise out of, relevant service, and where material contribution or aggravation is pleaded (subsection 10(2)). That creates a particular burden on claimants seeking to rely on subsection 9(1).

Rights to claim assessment: The Statement is applicable to claims as specified in section 5. Claimants therefore have the right to have their claims assessed with reference to this Statement where their claims are within the cited sections of the VEA or MRCA. Section 11 also guarantees that where a factor in this Statement refers to a disease covered by another Statement, the factors in that other Statement apply as in force from time to time; that cross‑reference protects the comprehensiveness of the factors framework.

No statutory duty of treatment or compensation in this instrument: The Statement itself does not create an express entitlement to treatment, compensation or benefits. Its function is to provide the causation framework that feeds into the determination of entitlements under the VEA and MRCA. The rights to compensation or rehabilitation arise from the underlying statutes (the VEA and MRCA) and the administrative processes that apply those statutes using Statements of Principles as guidance.

Operational obligations on decision‑makers: The instrument imposes an obligation on decision‑makers to adopt the definitions and factor tests it contains when adjudicating claims under the VEA and MRCA. That obligation includes applying the definition of Huntington disease in subsection 7(2), treating the ICD‑10‑AM code as a reference with the textual definition taking precedence (subsections 7(3)-(4)), applying the terminal event definition for death claims (subsection 7(5), Schedule 1), and ensuring the relationship to service requirements in section 10 are satisfied before finding connection.

In short, the instrument creates binding assessment criteria for decision‑makers and delineates the form of proof claimants must satisfy (at least one factor in section 9, related to relevant service, established on the balance of probabilities). It does not itself impose enforcement penalties or duties on third parties outside the claims determination process.

The Statement does not prescribe criminal penalties, administrative fines, or enforcement mechanisms in the manner of regulatory statutes. It is a determinative instrument made under subsection 196B(3) of the VEA that sets the factors decision‑makers must consider when assessing causation in claims relating to Huntington disease or death from Huntington disease. The instrument’s enforcement effect is therefore indirect: it binds adjudicative practice within the VEA/MRCA claims systems rather than imposing sanctions.

Application as an evidentiary and assessment tool: Sections 8-10 describe how the Statement must be used in adjudication. Section 8 states the RMA’s view that, on the medical‑scientific evidence available, it is more probable than not that Huntington disease and death from Huntington disease can be related to relevant service. That statement frames the standard of proof to be applied in claims assessment, namely the balance of probabilities. Decision‑makers are expected to apply these criteria when determining whether a claimant has satisfied the statutory tests for connection with service in the VEA and MRCA contexts (section 5).

Administrative effect and consequences: The practical consequence of applying this Statement is that claimants who cannot show that at least one of the listed factors exists and is related to their relevant service will be unable, under this Statement, to establish causation for Huntington disease or death from Huntington disease. This, in turn, will affect entitlement decisions under the VEA or MRCA: adverse causation findings may lead to rejection of claims or the denial of particular entitlements that depend on a finding of service connection. The Statement thus operates as the binding medical‑scientific template that informs decision‑makers’ determinations; the administrative consequence is evidentiary, not penal.

No specified compliance enforcement against third parties: The instrument contains no provisions that penalise medical practitioners, employers, or other private actors for failing to act. The single factor listed (inability to obtain appropriate clinical management) is a criterion for establishing connection, not an instrument for enforcing obligations on healthcare systems or providers.

Reassessment and cross‑Statement enforcement: Section 11 provides for factors in other Statements to apply where relevant. Decision‑makers must therefore ensure that any cross‑referenced Statements are applied “as in force from time to time.” Enforcement of that cross‑application is internal to the administrative decision process; there is no separate statutory penalty for failing to apply cross‑references beyond the legal remedies claimants can seek in administrative review or appeal channels under the VEA and MRCA frameworks.

Appeal and review mechanisms: The instrument itself does not set out appeal or review procedures. Appeals and reviews of decisions that apply this Statement will be governed by the procedural and review provisions of the VEA and MRCA, which are not reproduced in this instrument. The absence of internal penalty mechanisms in the Statement means that any challenge to the application of the Statement must be brought through the statutory review pathways available under the underlying Acts.

In short, enforcement is exercised through application in claims decision‑making rather than through penalties in the Statement. The Statement functions as a binding assessment rubric that will determine, administratively, whether claimants can establish a causal connection between Huntington disease or death from Huntington disease and relevant service.

The Statement is explicitly situated within the legal architecture of the VEA and the MRCA and interacts with those Acts by serving as the RMA’s determinative assessment framework for claims to which particular sections of those Acts apply. The instrument is made under subsection 196B(3) of the VEA (section 3) and applies to claims to which section 120B of the VEA or section 339 of the MRCA applies (section 5). Those cross‑references dictate the statutory contexts in which the Statement must be used.

Definitions and cross‑statutory scope: Schedule 1 imports and defines MRCA and VEA as shorthand references to the Military Rehabilitation and Compensation Act 2004 and the Veterans' Entitlements Act 1986 respectively (Schedule 1). The schedule also defines “relevant service” in terms that directly reference categories found in the VEA and MRCA (Schedule 1: relevant service). That definition limits the Statement’s reach to the specified classes of service and thereby interacts with the eligibility criteria embedded in the underlying statutes.

Relevance of other Statements of Principles: Section 11 creates an operational cross‑link with other Statements of Principles determined under subsection 196B(3) of the VEA. If a factor in this Statement refers to an injury or disease covered by another Statement, then the factors in that other Statement apply according to its terms “as in force from time to time” (section 11). This means that the Statement must be read and applied in conjunction with other applicable Statements when overlap occurs. Decision‑makers must therefore reconcile this Statement with any other Statements that are invoked by the factors at issue.

ICD coding and external classification systems: The instrument acknowledges the ICD‑10‑AM coding system by noting that Huntington disease attracts ICD‑10‑AM code G10, but makes clear that the statutory meaning for the instrument is the textual medical definition in subsection 7(2) (subsections 7(3)-(4)). The ICD reference thus operates as a classification pointer but does not displace the instrument’s textual definition. The instrument expressly refers to the ICD‑10‑AM, Tenth Edition, effective 1 July 2017 and includes bibliographic details (subsection 7(4)).

Repeal of prior Statement and continuity: Section 4 repeals the Statement of Principles concerning Huntington's chorea No. 38 of 2015. That repeal interacts with any ongoing claim assessments that were previously being handled under the earlier Statement. Decision‑makers must therefore switch to applying this 2023 Statement from its commencement date (section 2) when addressing claims within the statutory scope identified in section 5. The repeal may affect the legal framework applied to historic claims or appeals that span the transition.

Interaction with evidentiary and review regimes in the VEA and MRCA: While this Statement does not itself set out appeals or evidentiary rules, it is intended to be applied within the VEA and MRCA procedures. The underlying Acts prescribe the decision‑making, evidentiary standards, review and appeal processes. This Statement will be a determinative input to those processes. For instance, a determination that the single listed factor does not exist (section 9) will be a factual basis for rejecting a claim to which statutory review pathways under the VEA or MRCA may then apply.

Temporal and service nexus constraints: Section 10(2) imposes a limitation on the sole listed factor, making it applicable only where Huntington disease was suffered or contracted before or during but did not arise out of relevant service, and where the factor concerns material contribution to or aggravation of the disease. That limitation interacts with statutory notions of arising out of service and of aggravation materiality which are governed by the VEA and MRCA statutory tests and case law. Decision‑makers must therefore interpret “arise out of” and “material contribution or aggravation” in light of the underlying statutory frameworks when applying this Statement.

In sum, the Statement must be read and applied as part of a network of statutory instruments: it is an RMA determination that feeds into the VEA and MRCA decision‑making processes, it cross‑refers to other Statements of Principles, it uses ICD coding as a pointer while preserving a textual definition, and it replaces an earlier Statement. Its legal effect is realised through the interaction with the procedural and substantive provisions of the VEA and MRCA.

The instrument contains a concise amendment record within its own text. The Statement is designated as the Statement of Principles concerning Huntington disease (Balance of Probabilities) (No. 50 of 2023) (section 1). It bears a dated signature line indicating it was dated 24 April 2023 and was affixed with the Common Seal of the Repatriation Medical Authority at the direction of the Chairperson (header material). The instrument’s commencement date is 23 May 2023 (section 2).

Explicit repeal: Section 4 expressly repeals the Statement of Principles concerning Huntington's chorea No. 38 of 2015 (Federal Register of Legislation No. F2014L01852), which was previously made under subsection 196B(3) of the VEA. The repeal is absolute in form: the new Statement replaces the prior Statement in those contexts where this instrument applies. The text does not state transitional provisions or savings clauses; therefore, the repeal takes effect as part of the instrument’s operation on commencement. Practitioners and decision‑makers must therefore apply the new Statement from 23 May 2023 and not the 2015 Statement for claims to which this instrument applies.

No further amendments recorded: The instrument does not record any earlier amendments to itself or to the 2015 Statement apart from the repeal. There is no amendment schedule attached to this instrument and no indication of interim variations between the 2015 Statement and this 2023 Statement within the text itself. Any further changes to this Statement would require the RMA to determine a new Statement or an amendment under the relevant provision of the VEA.

Version identification: The instrument is identified by a number and year (No. 50 of 2023). This alphanumeric identification is the means by which decision‑makers and practitioners should cite the authoritative Statement. The explicit repeal reference to the earlier Statement provides clear lineage between the two determinative instruments.

Implications for claims spanning the change: The instrument does not set out a formal savings provision for claims that were made, under consideration, or appealed at the time of the transition from the 2015 Statement to this 2023 Statement. Because the text is silent on transitional application, the ordinary reading is that this Statement governs claims to which section 120B of the VEA or section 339 of the MRCA applies from the commencement date. Practitioners should therefore be aware that the determinative framework for claims was altered by the repeal and replacement on commencement.

Administrative provenance: The header information, signature and seal notation confirms that the instrument was executed at the direction of the Chairperson of the RMA. That administrative provenance is relevant for tracing the authoritative source and for record‑keeping in statutory compilations.

In sum, the amendment history recorded in the instrument is limited to the repeal of the 2015 Statement and the formal adoption and commencement of the 2023 Statement on the dates stated. No other amendments or historical notes are provided within the instrument’s text.

The Statement itself contains no references to judicial decisions, administrative determinations, or litigation history. It does not cite any cases, and no binding or persuasive judicial rulings are recorded in the text. The instrument is a stand‑alone determination by the Repatriation Medical Authority made under subsection 196B(3) of the VEA (section 3).

Absence of named cases in the instrument: Because the instrument does not name or summarise any previous tribunal or court decisions, there is no litigation history embedded in the Statement that instructs decision‑makers on how courts have interpreted equivalent provisions or scientific questions in relation to Huntington disease. The RMA instead communicates its view on the medical‑scientific evidence (section 8) and prescribes the factors to be applied in adjudication (sections 9-10).

Implications of silence: The lack of litigation references in the Statement leaves the application of certain phrases and concepts,such as “inability to obtain appropriate clinical management,” “material contribution,” “aggravation,” and the temporal limitation in subsection 10(2),to be worked out in administrative decisions and, potentially, in judicial review or appeal proceedings under the VEA and MRCA regimes. Any litigation that proceeds will be grounded in how decision‑makers applied this Statement when determining individual cases. The instrument does not provide precedential commentary on those interpretive questions.

Potential sources of future dispute identified by the text: The Statement’s design indicates particular areas where interpretive disagreement may arise, even though the instrument does not mention litigation. Those areas include the meaning and evidentiary threshold of “inability to obtain appropriate clinical management” (subsection 9(1)); the circumstances in which a disease “suffered or contracted before or during” but “did not arise out of” relevant service will nevertheless be materially contributed to or aggravated by service (subsection 10(2)); and the application of cross‑references to other Statements under section 11. Such interpretive questions could be the subject of administrative review or court proceedings under the VEA and MRCA, but the instrument itself does not report any such proceedings.

No recorded appeals or judicial consideration in the instrument: Because the Statement contains no litigation history, practitioners must look to the underlying statutory review pathways in the VEA and MRCA and to later administrative or judicial decisions for guidance on contested points. The Statement does, however, identify the standard of proof to be applied,balance of probabilities as articulated by the RMA in section 8,which will be the benchmark for adjudicators and courts reviewing factual findings.

In summary, the instrument contains no litigation or case law history. It sets out the RMA’s medical‑scientific view and the factors to be applied administratively; questions about the interpretation and application of those factors will become matters for administrative decision‑making and, if contested, for the statutory review and appeal mechanisms rather than being resolved within the Statement itself.

The Statement contains several narrow formulations and limits that create practical pitfalls for claimants, practitioners and decision‑makers. These are matters of textual operation and interpretation rather than policy judgements.

Single, narrow factor: Section 9 lists only one factor, namely “inability to obtain appropriate clinical management for Huntington disease” (subsection 9(1)). The absence of additional factors means that unless a claimant can establish that this particular factor exists and is related to relevant service, the Statement provides no other statutory pathway for establishing a service connection. Claimants who rely on other causal narratives will not find them in this Statement.

Temporal and causation constraint: Subsection 10(2) constrains the factor in subsection 9(1) to situations where the person’s Huntington disease was suffered or contracted before or during, but did not arise out of, the person’s relevant service, and where the factor applies to material contribution to or aggravation of the disease. That means the inability to obtain appropriate clinical management factor cannot be used where the Huntington disease arose out of the person’s service. The phrasing creates a potentially complex triage of situations: disease arising out of service is excluded from subsection 9(1), while disease existing before or during service may be the subject of a claim under subsection 9(1) only to establish material contribution or aggravation. Practitioners must be attentive to these temporal and causal permutations.

Vague statutory language: Terms such as “inability to obtain appropriate clinical management”, “appropriate clinical management”, “material contribution”, and “aggravation” are not defined in the instrument. The absence of statutory definitions invites contested interpretation about what forms of healthcare access, delay, refusal or shortage qualify as “inability”, and what quantum or causal link is needed for “material contribution” or “aggravation”. These uncertainties can be focal points for adversarial disputes and may require decision‑makers to develop evidentiary practices to fill the gap.

Service categories excluded by definition: The Schedule 1 definition of relevant service expressly excludes certain categories: eligible war service (other than operational service) and defence service (other than hazardous service and British nuclear test defence service). That selection of categories may unexpectedly exclude some veterans who assume all war or defence service is captured. Practitioners must map a claimant’s precise service classification against the Schedule 1 definition to confirm eligibility under this Statement.

ICD‑10‑AM code not determinative: Subsections 7(3)-(4) clarify that while Huntington disease is assigned ICD‑10‑AM code G10, the statutory meaning for the Statement is the textual definition in subsection 7(2). Reliance solely on diagnostic coding without reference to the textual definition may be insufficient. Decision‑makers must apply the textual definition rather than treating the code as dispositive.

Cross‑Statement complexity: Section 11 states that where a factor in this Statement refers to an injury or disease covered by another Statement, the factors in that other Statement apply as in force from time to time. The provision creates a procedural complexity: claimants and decision‑makers must identify any cross‑references and then consult potentially multiple Statements, each of which may have been amended or replaced. Failure to track relevant Statements or their current versions can lead to misapplication.

No penalties or treatment obligations: The Statement sets assessment criteria but does not impose obligations on healthcare providers or institutions to provide treatment. Where a claimant alleges inability to obtain appropriate clinical management, the Statement provides a path to establish service connection, but it does not itself create enforceable obligations on third parties to remedy healthcare access problems. Practitioners must not conflate the Statement’s causation role with a statutory duty to provide medical care.

Replaced earlier Statement without transitional text: The repeal of the 2015 Statement (section 4) is absolute in form and the instrument contains no transitional or savings clauses. Claims that cross the repeal date may be affected, and the instrument does not specify how evidence gathered under the earlier Statement should be treated. That gap may generate procedural arguments in individual cases.

Death claims and terminal events: Subsection 7(5) and Schedule 1 define “death from Huntington disease” to include death from a terminal event or condition contributed to by the person’s Huntington disease, and Schedule 1 provides illustrative examples of terminal events. However, the examples are not exhaustive and practitioners must consider how a particular proximate cause of death maps to the Schedule 1 definition. The instrument’s silence on evidentiary standards for causation of death can create disputes.

Application only to claims under specified statutory sections: Section 5 limits application to claims to which section 120B of the VEA or section 339 of the MRCA applies. Practitioners must ensure the claim falls within those statutory gateways; otherwise this Statement will not be the applicable determinative instrument.

In sum, the text’s narrow factor list, temporal constraints, undefined key terms, cross‑Statement interplay, and absence of transition rules are the principal operational “gotchas” that require careful attention when preparing or adjudicating claims.

Compliance, in the context of this Statement, means presenting a claim for determination under the VEA or MRCA that satisfies the assessment criteria the RMA has prescribed. The instrument itself sets the legal elements to be established; compliance is achieved by ensuring those elements are addressed in the claim and decision‑making process.

Confirm statutory applicability: First, verify that the claim is one to which section 120B of the VEA or section 339 of the MRCA applies, as the Statement only applies in those contexts (section 5). Check that the claimant’s service falls within the Schedule 1 definition of “relevant service”: eligible war service other than operational service; defence service other than hazardous service and British nuclear test defence service; or peacetime service under the MRCA (Schedule 1: relevant service). If the claimant’s service category is outside those definitions, this Statement will not govern the assessment.

Address the required factor(s): Ensure the claim engages at least one of the factors in section 9. This Statement contains a single factor: inability to obtain appropriate clinical management for Huntington disease (subsection 9(1)). A compliant claim must therefore identify and articulate how that factor applies in the claimant’s circumstances.

Establish relationship to service as required by section 10: The listed factor must be related to the person’s relevant service (subsection 10(1)). Where the claimant seeks to rely on subsection 9(1), subsection 10(2) requires that the factor be used only to establish material contribution to, or aggravation of, Huntington disease where the disease was suffered or contracted before or during the person’s relevant service but did not arise out of that service. In practical terms, a compliant claim must set out the timing of disease onset relative to service and explain how the asserted inability to obtain clinical management materially contributed to or aggravated the pre‑existing or concurrent disease.

Observe cross‑statement triggers: If the asserted factor refers to an injury or disease that is the subject of another Statement of Principles, ensure the factors in that other Statement are addressed and applied “as in force from time to time” (section 11). Compliance therefore requires checking the current versions of any cross‑referenced Statements and ensuring the claim addresses the relevant factors set out in them.

Use the instrument’s definitions: Apply the definitions in Schedule 1 to clarify terms in the claim. For death claims rely on subsection 7(5) and Schedule 1 to frame “death from Huntington disease” as death from a terminal event or condition contributed to by Huntington disease, and use the Schedule 1 list of terminal events for alignment with the instrument’s approach.

Adopt the proper standard of proof: The RMA states its view of the medical evidence and frames the causal question as whether, on the balance of probabilities, Huntington disease or death from Huntington disease is connected with relevant service (section 8). Compliance therefore requires structuring the claim to persuade decision‑makers on the balance of probabilities that the relevant factor(s) existed and were related to service as required by section 10.

Document temporal and causal assertions: Because subsection 10(2) creates a temporal limitation, a compliant claim should clearly set out when the Huntington disease was first suffered or contracted relative to service, whether it arose out of service, and how service materially contributed to or aggravated the disease via inability to obtain appropriate clinical management. Although the instrument does not list specific evidential items, claims must be framed to establish the factual elements the instrument requires.

Check for prior Statement implications: Take account of the repeal of the prior 2015 Statement (section 4). For claims that span the repeal date, be explicit about which Statement is being relied upon and why. The new Statement applies from its commencement date (section 2), so ensure the claim is lodged and argued with reference to the 2023 Statement where applicable.

Anticipate cross‑agency or statutory questions: Because this Statement is applied within the VEA and MRCA frameworks, compliance also requires attending to any procedural or evidentiary requirements in those Acts and their regulations. The Statement itself does not displace the review and appeal mechanisms in the underlying statutes.

Practical checklist (textually grounded):

• Confirm the claim falls under section 120B of the VEA or section 339 of the MRCA (section 5).
• Confirm the claimant’s service qualifies as “relevant service” per Schedule 1.
• Identify and set out how subsection 9(1) (inability to obtain appropriate clinical management) exists in the claimant’s circumstances.
• Demonstrate that the factor is related to relevant service in the manner required by section 10; where subsection 10(2) is relied upon, show the disease was suffered or contracted before or during service but did not arise out of service and that material contribution or aggravation is present.
• If other Statements are implicated, apply their factors as required by section 11.
• For death claims, frame the death as a terminal event or condition contributed to by Huntington disease using subsection 7(5) and Schedule 1 definitions.

Finally, because the Statement sets the causation framework rather than procedural steps or evidentiary checklists, practitioners should ensure that submissions and determinations explicitly map factual assertions to the statutory language of sections 7-11 and Schedule 1. That mapping is the mechanism by which compliance with the Statement’s requirements is demonstrated in the adjudicative process.